Exosomes are everywhere in regenerative marketing right now. Some products are well-validated and backed by serious research. Others are not. Here’s how to tell the difference — and why our medical team holds the products we work with to a high standard.
What an exosome actually is
An exosome is a small extracellular vesicle — a tiny biological packet typically between 50 and 100 nanometers in size — that cells use to communicate with each other. They carry signaling proteins, lipids, and RNA, and they help coordinate processes throughout the body, including those involved in inflammation modulation and tissue communication.
The science is real. The clinical interest is real. Unfortunately, that has created an opening for products marketed as exosomes that don’t actually meet the basic biological definition.
Red flag #1: “Trillions of cells”
When a product claims to contain trillions of cells, the first thing to ask is what’s actually being counted. Most legitimate exosome products are measured in billions, not trillions. Trillion-cell counts are typically not measuring biologically active particles. They’re counting total particles, including cellular debris and broken fragments — material that does nothing.
Dr. Scott Martin, who has lectured extensively on this topic, has called this category “trillion cell trash.” That’s a strong phrase, but it’s aimed at the marketing practice — not the patients who’ve been told a number that isn’t scientifically meaningful.
What objective validation looks like
Real exosomes carry specific surface markers — proteins on their outer membrane that confirm what they are. The markers most commonly used to verify true exosomes are CD9, CD63, and CD81, along with ALIX expression.
Validated exosome products use a technology called the ExoView scan, which doesn’t just count particles — it identifies specific surface markers on those particles to confirm the count is actually exosomes and not just cellular debris. A 2022 paper by Breitwieser et al. went into detail on this validation methodology.
This is what objective validation looks like: not a number on a brochure, but verified surface marker expression on the actual particles.
Red flag #2: A “white paper” instead of a peer-reviewed study
When evaluating any biologic product, there’s a meaningful difference between marketing materials and scientific validation.
A white paper is a document the company wrote about its own product. Sometimes white papers are useful technical summaries. Sometimes — increasingly — they are AI-generated documents formatted to look authoritative without containing peer-reviewed data.
A peer-reviewed, PubMed-indexed publication is something else entirely. It’s a study that other researchers have evaluated and that exists in the indexed scientific literature — something you can pull up by searching the product or methodology. Dr. Martin has called this “the receipt” — the highest form of validation.
The one question that cuts through the noise
When patients ask how to evaluate a clinic’s exosome product, our medical team suggests one question that does most of the work:
“Is there a peer-reviewed, PubMed-indexed published paper for the specific exosome product you use here — yes or no?”
If the answer is yes, ask to see it. Look at the materials and methods. The answer to that one question separates the products built on real validation from the ones built on marketing copy.
What we look for at RegenHaus
We don’t work with products simply because they’re available or because a sales rep has a compelling slide deck. The standards we apply when evaluating biologics include:
Size verification in the 50–100 nanometer range using validated technology. Surface marker expression — CD9, CD63, CD81 — verified through scans like ExoView. Peer-reviewed, PubMed-indexed studies on the specific product, not just the category. Sourcing transparency — chain of custody from donor to vial. FDA-registered processing facility with full traceability.
The bigger picture
Exosomes carry real scientific potential. That’s exactly why the standard for which products clinicians and patients trust should be high. “More cells” doesn’t mean better outcomes. Better evidence does.
REQUIRED DISCLAIMER
Educational content only. The information presented in this article is for general informational and educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. RegenHaus uses 361 HCT/P regenerative biologics, which are not FDA-approved to treat or cure any condition. Individual results vary. Please consult a licensed medical provider before considering any therapy or making changes to your health regimen.
